Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis - Top-Institutions - MDSpire

Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis

  • By

  • Min Duan

  • Yanjun Liu

  • Kexin Qiao

  • Zuojing Li

  • Dongsheng Zong

  • January 21, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Immuno-Oncology
    • Genitourinary Cancers

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Translational Research
    • Urologic Oncology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Cancer Immunotherapy

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Genitourinary Oncology

Original Source(s)

Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis

  • by Min Duan, Yanjun Liu, Kexin Qiao, Zuojing Li, Dongsheng Zong

  • January 21, 2026

Related Content

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors